Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus curcumin vs docetaxel plus placebo in first-line metastatic castration-resistant prostate cancer
2013-002138-20Phase 2Terminated
- Sponsor
- Centre Jean Perrin
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel plus curcumin with Docetaxel plus placebo (2 arms). Primary endpoint: Time to progression of metastatic disease. Started Aug 2013; status: terminated.
02
Drugs
curcumin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-002138-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002138-20.